Tissue Doppler Imaging (TDI) Versus Electrocardiography (ECG) Interventricular Pacing Delay Optimization in Cardiac Resynchronization Therapy (CRT)

Phase 3

Completed

• Conditions: Heart Failure; Cardiac Resynchronization Therapy
• Interventions: Device: Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves; Device: Electrocardiographic optimization of the interventricular pacing delay according to QRS width

• Registration Number: NCT01179997
• Lead Sponsor: Hospital Clinic of Barcelona

Brief Summary

The aim of this study was to compare the response to cardiac resynchronization therapy when the interventricular pacing interval was optimized by Tissue Doppler Imaging (TDI) to response when it was optimized following QRS width criteria.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-05
• Study First Submitted: 2010-08-05
• Study First Submitted QC: 2010-08-10
• Study First Posted: 2010-08-11
• Last Update Submitted: 2014-02-26
• Last Update Posted: 2014-02-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

• Patients submitted to de novo implant due to conventional cardiac resynchronization therapy indications.

Exclusion Criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tissue Doppler Imaging (TDI) optimization	Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves	Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
Electrocardiographic optimization	Electrocardiographic optimization of the interventricular pacing delay according to QRS width	Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram

Primary Outcome Measures

Name	Time	Method
6-month echocardiographic response		Reduction of the end-systolic volume (measured in mililiters according to transthoracic echocardiography) of \>10% as compared to the baseline value.

Secondary Outcome Measures

Name	Time	Method
6-month clinical response		Combined end-point consisting in no death due to cardiovascular reasons, no heart transplantation and distance increase of \>10% (measured in meters) in the 6-minute walking test.

Trial Locations

Locations (1)

Hospital Clinic Universitari; 🇪🇸 Barcelona, Catalonia, Spain